Enlivex (ENLV) Net Margin (2022 - 2025)
Enlivex (ENLV) posted quarterly Net Margin of 102.12% for Q1 2025, up 189.0% year-over-year from 35.34% in Q1 2024, and up 345.5% quarter-over-quarter from 41.6% in Q4 2024.
Enlivex (ENLV) Net Margin (2022 - 2025) Analysis & Trends
Enlivex's Net Margin history runs 4 years deep, the most recent figure standing at 102.12% for Q1 2025.
- In Q1 2025, Net Margin rose 189.0% year-over-year to 102.12%; the TTM figure through Mar 2025 stood at 67.97% (up 206426.0% YoY), while the FY2024 annual figure was 31.3%, down 4460.0% from the prior year.
- Net Margin for Q1 2025 stood at 102.12%, up from 41.6% in the prior quarter.
- The five-year high for Net Margin was 102.12% in Q1 2025, with the low at 57.79% in Q4 2023.
- The 4-year median for Net Margin is 86.11% (2022), against an average of 45.86%.
- The sharpest annual moves came in 2023 and 2025: Net Margin surged 1646 bps in 2023, then soared 189 bps in 2025.
- Enlivex's Net Margin stood at 77.88% in 2022, then sank by 174 bps to 57.79% in 2023, then advanced by 28 bps to 41.6% in 2024, then jumped by 346 bps to 102.12% in 2025.
- Business Quant data shows ENLV's Net Margin at 102.12% in Q1 2025, 41.6% in Q4 2024, and 100.24% in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.70 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 65.23 Bn | 60.05 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 60.16 Bn | 55.02 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 31.86 Bn | 28.55 Bn | 992.69 Mn | 12.74% |
| 7 | BioNTech SE | 28.24 Bn | 9.85 Bn | 668.28 Mn | -16.51% |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -3.12% |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 12.09% |
| 10 | Enlivex | 4.49 Mn | -1.26 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 102.12% |
| Dec 31, 2024 | -41.60% |
| Mar 31, 2024 | 100.24% |
| Dec 31, 2023 | -57.79% |
| Mar 31, 2023 | 94.34% |
| Mar 31, 2022 | 77.88% |